Aventis Streamlines R&D

Houlton, Sarah
September 2002
Pharmaceutical Executive;Sep2002, Vol. 22 Issue 9, p21
Trade Publication
Reports on Aventis' plan to reduce its research and development costs by spinning out a stake in one of its research units. Plans of the private equity house Warburg Pincus to invest in ProSkelia; Aventis' plan to spin off its gene therapy unit, Gencell.


Related Articles

  • Pipeline Payoff for Aventis?  // Chemical Week;6/26/2002, Vol. 164 Issue 26, p33 

    Focuses on the plans of Aventis to double the number of popular drugs in its portfolio by 2006. Information on drugs to be introduced by the firm; Claims of Aventis concerning its research and development efforts.

  • Aventis Unveils Strong Results And Ambitious Growth Targets.  // Chemical Market Reporter;2/18/2002, Vol. 261 Issue 7, p2 

    Presents information on the profits earned by pharmaceutical company Aventis in 2001. Effect of the positive earnings on the growth of the company; Plan of the company to expand its business; Remarks from Juergen Dorman, chairman of the board of the company.

  • GLOBAL INDUSTRY NEWS.  // Drug Discovery & Development;May2002, Vol. 5 Issue 5, p19 

    Reports global developments in the pharmaceutical industry as of May 2002. Approval on the codevelopment of transplant drug; Agreement between Genta and Aventis to commercialize Genasense; Alliance between Thermo Electron and Compaq Computer.

  • European Pharma Companies Post Strong Profits.  // Chemical Market Reporter;5/12/2003, Vol. 263 Issue 19, p14 

    Reports on the corporate profits of pharmaceutical companies in Europe. First quarter earnings of GlaxoSmithKline PLC; Increase of the pharmaceutical sales; Business sales growth of Aventis Inc.

  • Aventis Opens New API Facility for Lantus.  // Chemical Market Reporter;9/22/2003, Vol. 264 Issue 9, p3 

    Reports on the opening of a production facility by the pharmaceutical firm Aventis SA in Frankfurt, Germany. Project cost; Benefits of the facility for the firm; Investment of the company on the project.

  • The New Girindus Bets on Custom Manufacturing.  // Chemical Market Reporter;7/16/2001, Vol. 260 Issue 3, p29 

    Provides information on Girindus AG, a manufacturer of complex API and pharmaceutical intermediates in Germany. Primary targets of Girindus; Significant projects of Girindus; Implication of the acquisition of Aventis for Girindus.

  • Conquest scoops ...20m Aventis task.  // Marketing Week;5/6/1999, Vol. 22 Issue 14, p10 

    Reports on Conquest's acquisition of advertising duties for the worldwide launch of Aventis, the pharmaceutical firm formed from the merger of Rhone-Poulenc and Hoechst. Other advertising agencies which submitted bids for the account; Countries covered by Conquest's contract.

  • Aventis Pharma, On its Own, On Track For Strong Growth Through 2005. Jarvis, Lisa // Chemical Market Reporter;10/15/2001, Vol. 260 Issue 14, p8 

    Provides information on the agreement between Aventis company and Bayer Corp. for Bayer's purchase of Aventis' CropScience business. Significance of the agreement; Key products that dominate the portfolio of Aventis; Plan of Aventis to seek patent extension for its Allegra drug.

  • COMPANY SPOTLIGHT--Aventis.  // PharmaWatch: Cancer;November 2003, Vol. 2 Issue 11, p35 

    Focuses on Strasbourg, France-based pharmaceutical firm Aventis SA. Divisions of Aventis; Financial performance; Key executives.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics